Expression of Human Beta-Defensins in Children with Chronic Inflammatory Bowel Disease by Zilbauer, Matthias et al.
Expression of Human Beta-Defensins in Children with
Chronic Inflammatory Bowel Disease
Matthias Zilbauer
1,2*, Andreas Jenke
1, Gundula Wenzel
1, Jan Postberg
1, Andreas Heusch
1, Alan D.
Phillips
3, Gabriele Noble-Jamieson
2, Franco Torrente
2, Camilla Salvestrini
2, Robert Heuschkel
2, Stefan
Wirth
1
1Department of Paediatrics, HELIOS Klinikum Wuppertal, Germany, 2Department of Paediatric Gastroenterology, Addenbrooke’s Hospital, Cambridge, United Kingdom,
3Centre for Paediatric Gastroenterology, Royal Free Hospital, London, United Kingdom
Abstract
Background: Human beta-defensins (hBDs) are antimicrobial peptides known to play a major role in intestinal innate host
defence. Altered mucosal expression of hBDs has been suggested to be implicated in chronic inflammatory bowel disease
pathogenesis. However, little is known about expression of these peptides in children.
Methods: Intestinal biopsies were obtained from the duodenum (n=88), terminal ileum (n=90) and ascending colon
(n=105) of children with Crohn’s disease (n=26), ulcerative colitis (n=11) and healthy controls (n=16). Quantitative real-
time (RT) PCR was performed and absolute mRNA copy numbers analyzed for hBD1-3 as well as inflammatory cytokines IL-8
and TNF-alpha.
Results: Significant induction of hBD2 and hBD3 was observed in the inflamed terminal ileum and ascending colon of IBD
children. In the ascending colon induction of hBD2 was found to be significantly lower in children with Crohn’s disease
compared to ulcerative colitis. A strong correlation was found between inducible defensins hBD2 and 3 and the
inflammatory cytokines IL-8 and TNF-alpha, both in the terminal ileum and ascending colon.
Conclusion: Our study demonstrates distinct changes in hBD expression throughout the intestinal tract of children with IBD,
lending further support for their potential role in disease pathogenesis.
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Introduction
Human beta-defensins (hBDs) are a group of evolutionarily
conserved antimicrobial peptides (AMPs) known to play a major
role in innate host defence at various mucosal surfaces including
the gastrointestinal (GI) tract. Three of the most extensively
studied members are hBD1, -2 and -3. Under physiological
conditions, hBD1 is expressed constitutively by intestinal epithelial
cells while hBD2 and -3 are induced during infection and
inflammation [1,2]. In addition to their potent antimicrobial
properties against commensal and pathogenic bacteria [3,4], beta-
defensins have been shown to function as multieffector molecules
capable of enhancing host defence by recruiting various innate as
well as adaptive immune cells to the site of infection, induction of
neovasculogenesis and enhancing wound closure [5,6,7]. Given
these versatile functions it is not surprising that impaired
expression and/or function of these peptides has been implicated
in the development of several diseases, including chronic
inflammatory bowel disease (IBD). The two major entities are
Crohn’s disease (CD) and ulcerative colitis (UC), which differ in
disease distribution as well as histological changes of the affected
bowel segment. While CD causes transmural inflammation
throughout the entire GI mucosa, changes in UC are restricted
to the colonic mucosa. IBD disease pathogenesis is highly complex
and remains incompletely understood. However, increasing
evidence suggests that impaired or altered innate host defence
mechanism(s) are likely to play a major role as highlighted by the
association of NOD2 mutations and CD [8].
Several studies havereported on modulated hBD expression inthe
mucosa of IBD patients. For example, both constitutively expressed
hBD1 as well as inducible defensins hBD-2 and -3 were found to be
markedly up-regulated in the inflamed colonic mucosa of adults with
IBD [9,10,11]. Moreover, induction seemed to be less pronounced in
CD compared to UC [9]. In addition to mucosal hBD expression,
reduced gene copy numbers for hBD1 and hBD2 have been shown to
predispose to the development of CD - further highlighting the likely
involvement of these peptides in IBD disease pathogenesis [12,13].
However, studies published to date have been performed almost
exclusively on adult patients with longstanding disease, and very little
i sk n o w na b o u th B De x p r e s s i o ni np a e d i a t r i cI B D .
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e15389The aim of this study was to investigate expression of hBD1-3 in
small and large bowel biopsies of children with IBD and healthy
controls. Furthermore, the potential impact of mucosal inflamma-
tion on hBD expression was analysed by assessing histological
changes and mucosal expression of the inflammatory cytokines IL-
8 and TNF-alpha.
Results
Intestinal human beta-defensin expression in healthy
children
First we analysed expression of hBD1-3 throughout the
intestinal tract of healthy children. hBD1 was expressed constitu-
tively in small and large bowel biopsies with levels being
significantly higher in the colon compared to duodenum and TI
(Figure 1a). In contrast to hBD1, inducible defensins hBD2 and -3
were infrequently expressed, with low copy numbers and no
significant differences between bowel segments (Figure 1a and b).
In addition to beta-defensins we also analysed mucosal expression
of inflammatory cytokines IL-8 and TNF-alpha. As shown in
Figure 1d and e, significantly higher levels for both IL-8
(P=0.0222) and TNF-alpha (P=0.0014) were found in the
healthy TI compared to duodenum and ascending colon.
Intestinal hBD1 expression in children with IBD and
healthy controls
Next we investigated expression of hBD1 in our patient cohort.
Comparing hBD1 levels in children with UC and healthy controls,
no difference was found in any of the bowel segments tested
(Figure 2a–c). In contrast, significantly higher mRNA copy
numbers were observed in duodenal and TI biopsies obtained
from CD children compared to controls. Despite higher hBD1
levels in colonic biopsies of CD patients, this did not reach
statistical significance (Figure 1c). However, subdividing IBD
biopsies further into histologically inflamed (I) and non-inflamed
(NI), revealed significantly higher hBD1 levels in the non-inflamed
ascending colon and TI (Figure 2d and e).
Expression of inducible beta-defensins and inflammatory
cytokines in paediatric small bowel biopsies
As shown in Figure 1 expression levels of hBD2 and hBD3 are
low in the healthy mucosa. However, up-regulation has been
shown to occur during infection and inflammation. We therefore
analysed expression of hBD2 and -3 as well as inflammatory
cytokines IL-8 and TNF-alpha in small bowel biopsies of our
patient cohort. As shown in Figure 3a-d, significant up-regulation
of both inducible beta-defensins was found in the duodenum of
CD children. However, interestingly, this was despite the absence
of significant inflammation as assessed by histological examination
and expression of inflammatory cytokines IL-8 and TNF-alpha
(Figure 3c and d). In contrast to the duodenum, significantly
increased levels of both hBD2 and hBD3 were found exclusively in
the inflamed mucosa of CD patients, which also expressed high
levels of IL-8 and TNF-alpha.
Colonic expression of inducible beta-defensins and
inflammatory cytokines in paediatric IBD
In addition to the small bowel, we also analysed beta-defensin
expression in colonic biopsies of IBD patients. Similar to our
findings in the TI, expression of hBD2 and -3 was significantly
induced in the inflamed mucosa of children with CD and UC
(Figure 4a and b). Interestingly, induction of hBD2 was found to
be significantly less pronounced in CD compared to UC biopsies
despite equal levels of inflammatory cytokines IL-8 and TNF-
alpha (Figure 4c and d). In contrast to hBD2, no difference was
found in hBD3 levels comparing inflamed colonic mucosa of both
patient groups. Significant induction of IL-8 and TNF-alpha in the
histologically inflamed (I) colonic mucosa was observed. Moreover,
increased levels of both inflammatory cytokines were also noted in
histologically non-inflamed (NI) colonic biopsies of CD children
(Figure 4c and d).
Correlation of intestinal beta-defensin and inflammatory
cytokine expression
Having noted significant changes of both constitutively and
inducible beta-defensins in the inflamed GI mucosa if children
with IBD, we analysed the correlation between inducible defensins
hBD2 and hBD3 and the inflammatory cytokines within each
bowel segment. For these calculations, both results of all children
with IBD (inflamed and non-infloamed) and those of healthy
control biopsies were included. As shown in Table 1, a highly
significant correlation of hBD2 and hBD3 with IL-8 as well as
TNF-alpha was found in TI and AC biopsies. In contrast,
correlation analysis in the non-inflamed duodenum were largely
non significant.
Discussion
Human beta-defensins have been shown to play a key role in
intestinal innate host defence [14]. It is therefore not surprising
that altered expression and/or function of these peptides has been
implicated in IBD disease pathogenesis. However, little is known
about the role and regulation of hBDs in paediatric patients. In
this study we have investigated beta-defensin gene expression in
over 250 intestinal biopsies obtained from children with IBD and
healthy controls.
First we analysed expression of hBD1-3 and the inflammatory
cytokines TNF-alpha and IL-8 in the mucosa of healthy children.
We were able to confirm previously reported data showing
constitutive expression of hBD1 throughout the GI tract while
hBD2 and -3 were either not detected or present in low mRNA
copy numbers [1]. Following this we investigated hBD expression
in children with IBD. Here we observed significant induction of
hBD2 and hBD3 in the inflamed TI and AC of children with CD
as well as UC. Moreover, hBD2 induction in the inflamed colonic
mucosa of CD children was found to be significantly less
prominent compared to UC despite equal levels of IL-8 and
TNF-alpha. This data is consistent with previously published
findings on adult populations [9,15], however it seems that hBD2
expression is less impaired in paediatric compared to adult CD,
perhaps suggesting that further regulation occurs in long standing
disease. In contrast to hBD2, no significant difference in TI or
colonic hBD3 induction was observed between patient groups.
This is again in contrast to previously published data on adult
patients [9].
With regards to expression of hBD1, we found mRNA levels to
be increased in the small and large bowel of CD patients only,
whereas levels in UC biopsies did not differ from healthy control
samples, further highlighting distinct differences between CD and
UC. Interestingly, sub-dividing biopsies into inflamed and non-
inflamed samples revealed that hBD1 up-regulation was mainly
found in the non-inflamed mucosa of CD children. This however
has to be interpreted with caution since it could simply signify a
degree of epithelial cell loss within the inflamed tissue.
Given the fact that changes of hBD expression were particularly
prominent in the inflamed small and large bowel, we analysed
correlation of hBDs with inflammatory cytokines IL-8 and TNF-
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PLoS ONE | www.plosone.org 2 October 2010 | Volume 5 | Issue 10 | e15389Figure 1. Expression of hBDs and inflammatory cytokines in the intestinal mucosa of healthy children. Biopsies were obtained from
duodenum (D), terminal ileum (TI) and ascending colon (AC). Absolute mRNA copy number for hBD1-3 (a-c), IL-8 (d) and TNF-alpha (e) in each biopsy
were quantified by real-time PCR using the standard curve method. Expression levels were normalized against the geometrical mean of two selected
housekeeping genes (GPDH and b-actin). Data is expressed as the mean 6 standard error of mean (SEM). The number of biopsies analysed for each
patient group is stated (n). Values for P,0.05 were considered to be statistically significant.
doi:10.1371/journal.pone.0015389.g001
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the inducible defensins hBD2 and hBD3 and both inflammatory
cytokines in the TI and AC confirming previous reports [16]. In
contrast, analysis in the non-inflamed duodenum proved to be
largely non-significant, suggesting regulatory mechanisms may
vary between bowel segments.
Overall our data suggests differential regulation of hBDs in the
mucosa of children with IBD, dep e n d i n gb o t ho nd i s e a s et y p e
Figure 2. Expression of hBD1 in mucosal biopsies from IBD children and healthy controls. Expression of hBD1 in the duodenum (a),
terminal ileum (b) and ascending colon (c) was analysed in children with Crohn’s disease (CD), ulcerative colitis (UC) and healthy controls (con). For
the TI (d) and AC (e), biopsy samples from CD patients were subdivided into histologically non-inflamed (NI) and inflamed (I). Data is expressed as the
mean 6 standard error of mean (SEM) of absolute mRNA copy numbers. The number of biopsies analysed for each patient group is stated (n). Values
for P,0.05 were considered to be statistically significant.
doi:10.1371/journal.pone.0015389.g002
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PLoS ONE | www.plosone.org 5 October 2010 | Volume 5 | Issue 10 | e15389and region of the gut. Specifically, induction of hBD2 and hBD3
in the inflamed TI and AC mucosa is likely to be of biological
relevance for IBD disease pathogenesis. However, the exact
mechanism(s) involved remain to be elucidated. Despite the
observed reduction in hBD2 induction in CD compared to UC,
one should be cautious to conclude that an impaired expression
of hBDs is a main causative feature of CD. Importantly, in
addition to the well-documented antimicrobial properties of
hBDs, evidence is rapidly increasing on their role as potent
immune modulators capable of enhancing inflammatory pro-
cesses and hence potentially contributing to the onset and/or
persistence of chronic intestinal inflammation [7]. Functional
studies are required to shed further light on these important
questions.
Figure 4. Expression of inducible beta defensins and inflammatory cytokines in colonic biopsies of children with IBD and healthy
controls. Expression of hBD2 (a), hBD3 (b), IL-8 (c) and TNF-alpha (d) was analysed in biopsies obtained from the ascending colon of children with
Crohn’s disease (CD), ulcerative colitis (UC) and healthy controls (con). Biopsies from CD and UC patients were subdivided into histologically non-
inflamed (NI) and inflamed (I). Data is expressed as the mean 6 standard error of mean (SEM) of absolute mRNA copy numbers. The number of
biopsies analysed for each patient group is stated (n). Values for P,0.05 were considered to be statistically significant.
doi:10.1371/journal.pone.0015389.g004
Figure 3. Expression of inducible beta defensins and inflammatory cytokines in small bowel biopsies of IBD children and healthy
controls. Expression of hBD2 (a and e), hBD3 (b and f), IL-8 (c and g) and TNF-alpha (d and h) was analysed in the duodenum (a–d) and TI (e–h) of
children with Crohn’s disease (CD), ulcerative colitis (UC) and healthy controls (con). For the TI, biopsy samples from CD patients were subdivided into
histologically non-inflamed (NI) and inflamed (I). Data is expressed as the mean 6 standard error of mean (SEM) of absolute mRNA copy numbers. The
number of biopsies analysed for each patient group is stated (n). Values for P,0.05 were considered to be statistically significant.
doi:10.1371/journal.pone.0015389.g003
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Patient cohort and sample collection
Patients for this study were recruited over a period of 18 months
(08/2008 to 02/2010) from 3 paediatric gastroenterology centres
in the UK (London and Cambridge) and Germany (Wuppertal). A
total number of 53 children were included consisting of 26 CD
(mean age 12.6 years, 15 female), 11 UC (mean age 11.2 years, 4
female) and 16 healthy controls (age mean 12.1 years, 9 female).
Diagnosis of CD and UC was based on standard criteria using
clinical, radiological, endoscopic, and histopathological findings in
accordance with Porto criteria [13]. As healthy control group,
children with macroscopically and histologically normal mucosa as
well as no evidence of any underlying GI condition were recruited.
Endoscopy was performed by experienced paediatric gastroenter-
ologists, who collected 1–2 additional biopsies within close
proximity of the area in which biopsies were taken for routine
histology. Biopsies were collected from the duodenum (D; n=88),
terminal ileum (TI; n=90) and ascending colon (AC; n=105).
Ethical approval for this study was obtained for all participating
hospitals and fully informed written consent was taken from legal
guardians and children where appropriate.
Histological scoring and tissue storage
Biopsies taken for routine histological examination were
evaluated by two experienced paediatric histopathologists and
the presence of inflammation recorded. Tissue specimens were
classified as inflamed if any of the following features were present:
significant infiltration of inflammatory cells, ulceration, cryptitis or
crypt abscesses. In the absence of these findings, tissue was
classified as non-inflamed. Biopsy samples for real-time (RT)
analysis were directly transferred into RNAlater (QIAGEN) and
stored at 280uC until further processing.
RNA extraction and reverse transcription PCR
RNA was extracted from biopsies using QIAGEN RNeasy
extraction kit according to the manufacturer’s instructions.
Integrity of extracted RNA was analyzed by agarose gel
electrophoresis and quantified using spectrophotometric absor-
bance at 260 nm. Following, 500 ng of RNA were reverse
transcribed using QIAGEN QuantiFast kit, which included
DNAse treatment to eliminate any residual genomic DNA.
Real-Time (RT)-PCR and absolute quantification of mRNA
copy numbers
Real Time (RT)-PCR analysis was performed on a Rotor Gene
6000 real time rotary analyzer (Corbett Life Science) using SYBR
green methodology. Briefly, reverse transcribed cDNA corre-
sponding to 12.5 ng of RNA were used in a 20 ml PCR reaction
containing 10 ml QuantiFast SYBR green master mix (QIAGEN),
2 ml gene specific primers (100 nM of each primer) and 8 ml
cDNA in H2O. Primer sequences used were as follows: hBD1:
forward59-acc ttc tgc tgt tta ctc tct gct-39 reverse 59-gac att gcc ctc
cac tgc t-39 hBD2: forward 59-cca gcc atc agc cat gag ggt-39
reverse 59-gga gcc ctt tct gaa tcc gca-39 hBD3 forward 59-agc cta
gca gct atg agg atc-39, reverse 59-ctt cgg cag cat ttt cgg cca-39
TNF-alpha forward 59-ccc agg gac ctc tct cta atc a-39 reverse 59-
gct aca ggc ttg tca ctc gg-39 IL-8 forward 59-atg act tcc aag ctg gcc
gtg gc-39 reverse 59tct cag ccc tct tca aaa act tc-39. Cycling
conditions were as follows: 10 min 95uC, followed by 40 cycles at
95uC for 20 sec and 60uC for 40 sec. At the end of each run
melting point analysis was performed to validate specificity of PCR
transcripts. All samples were analyzed in triplicate. Absolute
quantification was performed using the standard curve method.
Briefly, for each gene tested, reference plasmids containing the
target sequence were produced (by cloning into p-drive Vector)
and the amount of plasmid measured using a Nano-drop
Spectrophotometer (ND-1000, Labtech International). Copy
numbers were calculated using Avogadro’s formula and standard
curves generated by performing serial dilutions of plasmid samples
ranging from 10
7 to 10
2 copies. In each PCR run a reference
standard was included and the primer specific standard curve
imported using software provided by Corbett Life Science.
All samples were normalized against the geometric mean of two
reference genes (GAPDH and b-actin), which were chosen after
testing a group of 7 commonly used reference genes using geNorm
Visual Basic application for Microsoft Excel as described
previously [17].
Statistical analysis
Mean expression levels of all genes tested were obtained from
triplicate real time PCR measurements. Data are presented as the
mean +/2 standard error of mean (SEM). Testing for significant
differences between groups was performed using an unpaired t-test
for values with Gaussian distribution and the Mann-Whitney test
for values without Gaussian distribution. The Kolmogorov-
Smirnov test was utilised to determine Gaussian distribution. For
correlation analysis Spearman’s rank coefficient was calculated.
Values for P,0.05 were considered statistically significant. All
analysis were performed using Graphpad Prism version 5
(Graphpad Software, San Diego, CA).
Table 1. Correlation of intestinal beta-defensin and
inflammatory cytokine mRNA expression levels.
Duodenum (n=88) TNF-alpha IL-8
hBD2 ns *
P=0.389 P=0.047
r=0.09295 r=0.2124
hBD3 ns ns
P=0.1982 P=0.2295
r=20.1385 r=0.129
Terminal Ileum (n=94) TNF-alpha IL-8
hBD2 * ***
P=0.0143 P,0.0001
r=0.2519 r=0.6101
hBD3 * ***
P=0.0269 P,0.0001
r=0.2283 r=0.5951
Ascending Colon (n=105) TNF-alpha IL-8
hBD2 *** ***
P,0.0001 P,0.0001
r=0.393 r=0.6556
hBD3 ** ***
P=0.0011 P,0.0001
r=0.3145 r=0.5738
Correlation of gene expression between beta-defensins (hBD2 and hBD3) and
inflammatory cytokines (IL-8 and TNF-alpha) in the duodenum, terminal ileum
and ascending colon was tested by calculating Spearman’s rank correlation
coefficient (r). The number of biopsies included into calculations is stated (n).
Values for P,0.05 were considered to be statistically significant.
doi:10.1371/journal.pone.0015389.t001
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